Landscapes / Companies
Vanda Pharmaceuticals not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 approved
1 in Phase 3
Drugs
9
in active trials · 12 in all
Trials
15 active
55 since 2021
Drugs9
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Approved | 1 Dec 2026soonPhase 3 trial completes | |||
| Next date | 1 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Motion Sickness, Nausea and Vomiting and 1 more | ||||
| Open drug page | |||||
Atypical antipsychotic |
Approved | Nov 2027Phase 3 trial completes | |||
| Next date | Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Schizophrenia, Bipolar I Disorder and 2 more | ||||
| Open drug page | |||||
Melatonin receptor agonist |
Approved | Nov 2027Phase 3 trial completes | |||
| Next date | Nov 2027 · Phase 3 trial completes | ||||
| Also tested for | Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm and 3 more | ||||
| Open drug page | |||||
— |
Approved | Mar 2028Phase 3 trial completes | |||
| Next date | Mar 2028 · Phase 3 trial completes | ||||
| Also tested for | Major Depressive Disorder (MDD) | ||||
| Open drug page | |||||
Sphingosine 1-phosphate receptor modulator |
Actelion |
Approved | Aug 2028Phase 3 trial completes | ||
| Next date | Aug 2028 · Phase 3 trial completes | ||||
| Also tested for | Moderate-to-severe Chronic Plaque Psoriasis, Ulcerative Colitis (UC) | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Social Anxiety Disorder (SAD) | ||||
| Open drug page | |||||
— |
Phase 1/2 | Mar 2027Phase 1/2 trial completes | |||
| Next date | Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD) | ||||
| Open drug page | |||||
— |
Phase 2 | Dec 2027Phase 1 trial completes | |||
| Next date | Dec 2027 · Phase 1 trial completes | ||||
| Also tested for | Relapsed or Refractory Hematologic Malignancies, Onychomycosis of Toenail | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Dry Eye | ||||
| Open drug page | |||||
About
- No active trial
- Double-blind, Imsidolimab, Open-label
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021